Upcoming Conferences & Presentations
A regularly invited speaker at major international conferences, I also chair key presentation sessions and organize high level topical symposia. My ambitious schedule (see below) recognizes the urgency of my scientific mission, my dedication to the effective dissemination of scientific results, and my value in R&D strategy and policy formulation.
Following is a list of my upcoming events. For my previous activities see the list of prior events that I’ve presented at and/or organized.
DRIVE-AB Conference: Stimulating innovation, sustainable use and global access to antibiotics
2-3 June, Amsterdam, NL
U. Theuretzbacher: Panel discussion – The way forward
4-7 May, Dubai, UAE
U. Theuretzbacher: New Molecules against resistant Pseudomonas aeruginosa
U. Theuretzbacher: Worldwide initiative to control AMR and role of Anti-microbial stewardship
2-5 March, Hyderabad, India
U. Theuretzbacher: The antibiotic pipeline: What can we expect?
22-23 February, Bielefeld, Germany
U. Theuretzbacher: Forschungslücken schließen
10 February 2016, The Wellcome Trust, London
U. Theuretzbacher: A withering vine or golden opportunity? The changing face of the global research and development landscape
22-24 September, San Diego, CA, USA
23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Copenhagen, 25-28 April2015
U. Theuretzbacher: Drug pipeline for Gram-negative bacteria
15 April, 13:30
13. Symposium Infektionsmedizin in Tübingen, Germany, 7 March 2015
U. Theuretzbacher: Neue Antibiotika für gramnegative Bakterien
Meeting the challenge of antimicrobial resistance: Working together across political, professional and public fronts
Roundtable three: Re-stoking the therapy pipeline: How to stimulate the development of new antibiotics, diagnostics and novel therapies
Thursday 5 February 2015
U. Theuretzbacher: The changing face of pharma industry research
22 – 24 October 2014, Vienna, Austria
U. Theuretzbacher: Scientific organiser
U. Theuretzbacher: How do you “re-develop” an old antibiotic: experience from AIDA
Bringing PK and PD into the Clinic
21 August 2014, Medical University Innsbruck, Austria
U. Theuretzbacher: Optimising therapy to minimise emergence of resistance.
U. Theuretzbacher: Developmental beta-lactamase inhibitors in phase 2/3 clinical trials.
International Congress on Infectious Diseases (ICID)
16. Klinisch-Mikrobiologisch-Infektiologischen Symposium
28th International Congress of Chemotherapy and Infection
Official Symposium, 7th June, 16:00-17:30
|May 2013||1st International Conference on Polymyxins2 – 4 May, 2013, Monash Centre in Prato, Italy
U. Theuretzbacher: Impact of resistance on treatment and dosing decisions.
U. Theuretzbacher: Dosing considerations in cancer patients.
Antimicrobial Stewardship in Hospitals, ESCMID Postgraduate Education Course
U. Theuretzbacher: Improving dosing regimens to minimise resistance.
|March 2013||Superbugs&Superdrugs– A Focus on Antibacterials March 4-5, 2013, 2012, London, UK
Session: Public/Private Partnerships
Round Table Discussion: Richard Bax (TranScrip Partners), Richard Bergstrom (Director General, European Federation of Pharmaceutical Industries and Associations, EFPIA), Ursula Theuretzbacher (Center For Anti-Infective Agents), Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commission).
|4th World Annual PK/PD Summit Nov 27-29, 2012, Frankfurt, GermanyWorkshop: Antimicrobial dose finding and optimising for early clinical studies of bacterial infections
|13th Asia-Pacific Congress of Clinical Microbiology and Infection(APCCMI)Oct 25-28, 2012, Beijing, ChinaSecuring New Antibiotics (co-organized by ISC Antibiotics of the Future WG)
8 – 12 Sept 2012, San Francisco, USA
Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
|Post-ICAAC ISAP symposiumSept 12 2012, San Francisco, USA
|ESCMID Summer School11th ESCMID Summer School,21 – 27 July 2012, Innsbruck, AustriaProgramme:U. Theuretzbacher: State-of-the-art therapy of serious Gram-positive bacterial infections, including MRSA.U. Theuretzbacher: Catheter-related infections: diagnosis and how to manage?U. Theuretzbacher: Surgical site infections, how can we prevent them?|
|First International Symposium on Enterobacteriaceae producing Carbapenemases
March 2, 2012, Paris, France
|March 2012||Superbugs & Superdrugs – A Focus On Antibacterials,
March 6, 2012, London, UK
The Global Need for New Antibiotics – International Actions and Implications for Antibacterial Drug Development
|Antibacterial Drug Development
Integrating Chemistry and Biology
April 17-18, 2012, San Diego, CA, USA.
U. Theuretzbacher: PK/PD and Emergence of Resistance
With antibiotic usage, emergence of resistance is unavoidable. However, several factors in the drug development process can be adjusted to reduce the risk of rapid emergence of resistance in clinical settings. During drug development, PK/PD models are appropriate tools for mitigating the risk of resistance.
|My activities during the ECCMID 2012 in London, UK include:
Optimising treatment based on a pharmacodynamic approach: an interactive workshop using clinical cases
arranged with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
Convenors: Ursula Theuretzbacher, Vienna, Austria & Johan Mouton, Nijmegen, Netherlands
Update in drug development
Considering pharmacodynamic effects in antifungal treatment strategies
Colistin use in clinical practice
Faculty: M. Paul, J.W. Mouton, W. Couet, Y. Carmeli
Interested in seeing more? Here is the list of prior events that I’ve presented at and/or organized.